Drug discovery and development in idiopathic pulmonary fibrosis: the changing landscape.
Idiopathic pulmonary fibrosis (IPF)
drug development
emerging therapies
failures
new strategies
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
11 Oct 2024
11 Oct 2024
Historique:
received:
15
02
2024
revised:
28
08
2024
accepted:
08
10
2024
medline:
14
10
2024
pubmed:
14
10
2024
entrez:
13
10
2024
Statut:
aheadofprint
Résumé
Idiopathic pulmonary fibrosis (IPF) is an area of high unmet clinical need and high research activity in the pharmaceutical and biotech industries. The two approved therapies, nintedanib and pirfenidone, have issues with efficacy and tolerability. Despite a considerable number of development programs reaching late-stage Phase 2b or 3 clinical trials, no drug other than nintedanib and pirfenidone has successfully demonstrated a benefit for patients. An analysis of these failures, and consideration of the trajectories of some of the current development projects, may offer novel paradigms for choosing modes-of-action and for the development of successful drugs.
Identifiants
pubmed: 39396672
pii: S1359-6446(24)00332-5
doi: 10.1016/j.drudis.2024.104207
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104207Informations de copyright
Copyright © 2024. Published by Elsevier Ltd.